Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| KFRCKforce Inc | $967.27M | 25.8× | $1.33B | -5.4% | $34.83M | $330K | $14.97M | Fair valued |
| MNTNMNTN, Inc. | $972.07M | 17.3× | $290.09M | +28.6% | -$6.43M | $237.28M | — | Undervalued |
| QMCOQuantum Corp | $973.82M | — | $279.58M | +2.0% | -$101.05M | $54.45M | $8.86M | Overvalued |
| SBSISouthside Bancshares Inc | $973.83M | 12.9× | $237.04M | -8.1% | $69.22M | $397.26M | $222M | Fair valued |
| CIMChimera Investment Corp | $974.82M | — | — | — | — | $444.04M | $252.55M | Undervalued |
| CACCamden National Corp | $979.69M | 11.1× | $255.78M | +44.5% | $65.16M | $99.9M | $508.39M | Fair valued |
| UTLUnitil Corp | $981.86M | 17.1× | $536M | +8.3% | $50.2M | $9.2M | $962.9M | Fair valued |
| CPFCentral Pacific Financial Corp | $982.26M | 12.2× | $292.7M | +16.9% | $77.48M | $383.27M | $100.61M | Fair valued |
| IMMXImmix Biopharma, Inc. | $984.02M | — | — | — | — | $225.49M | $1M | Fair valued |
| SVCService Properties Trust | $984.27M | — | $1.41B | -5.6% | -$202.32M | $5.51M | $5.65B | Fair valued |
| TRSTTrustco Bank Corp N Y | $985.05M | 16.1× | $187.92M | +9.4% | $61.14M | $696.64M | $144.74M | Fair valued |
| FMCBFarmers & Merchants Bancorp | $985.33M | 10.1× | $242.79M | +6.8% | $93.61M | $278.64M | $1.66M | Fair valued |
| KROKronos Worldwide Inc | $986.39M | — | $1.86B | -1.5% | -$110.9M | $26.6M | $588.6M | Fair valued |
| INRInfinity Natural Resources, Inc. | $986.53M | 6.5× | $350.38M | +36.0% | $13.84M | $25.88M | $1.87M | Undervalued |
| AMPHAmphastar Pharmaceuticals, Inc. | $987.35M | 13.6× | $719.89M | -1.7% | $98.09M | $223.61M | $685.83M | Fair valued |
| FBYDFalcon's Beyond Global, Inc. | $988.26M | — | $14.9M | — | $6.31M | $3.09M | $18.61M | Overvalued |
| CADLCandel Therapeutics, Inc. | $989.39M | — | $125K | 0.0% | -$18.79M | $201.57M | $1.69M | Fair valued |
| AEBIAebi Schmidt Holding AG | $990.99M | 37.4× | $1.53B | +40.6% | $9.74M | $109.73M | $786.57M | Fair valued |
| LXRXLexicon Pharmaceuticals, Inc. | $992.25M | — | $49.8M | +729.9% | -$50.34M | $40.92M | $59.24M | Fair valued |
| ASTEAstec Industries Inc | $996.31M | 51.5× | $1.41B | +8.1% | $38.8M | $76.8M | $393.4M | Fair valued |